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In this study, we investigated the immunomodulatory effects of a supplemented
killed inﬂuenza virus (V) by Echinacea purpurea (E) and Nigella sativa (N) extracts
and effect of changing the route of immunization from intramuscular (IM) to
intraperitoneal (IP). At the 2nd-, 3rd- and 4th-week post-IM immunizations (WPIMI),
the supplemented V with N (VN) induced the most signiﬁcant IgM response unlike N
alone. At the 2nd WPIMI, V or VN induced the highest signiﬁcant IgG levels. At the
2nd-week post-IP immunization (WPIPI), E and VN induced the most signiﬁcant IgG
levels. Both at the 3rd and 4th WPIMI or WPIPI, various treatments induced signiﬁcant
increases in IgG. At the 4th WPIMI, E, V, and V with E (VE) induced signiﬁcant
increases in the CD4+ thymocytes while all IP treatments caused signiﬁcant increase
in their counts. V and VN induced the most signiﬁcant IM induction of CD8+
thymocytes while their best IP stimulation was induced by N, VE, and VN. At the
4th WPIMI, various treatments caused signiﬁcant increases in the mesenteric lymph
node (MLN) CD4+, CD8+ counts. WPIPI with V or VE caused signiﬁcant increases
in both the CD4+- and CD8+ MLN cells, whereas VN signiﬁcantly induced
CD8+ MLN cells only. WPIPI with various treatments caused signiﬁcant increases
in the B-cell counts and the peak was obtained by VN.
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Introduction
Inﬂuenza viruses fall among extensively studied pathogens, yet available
control measures still require continuous improvement and updating to enable
facing continuous challenges by emerging pandemics. Antiﬂu vaccines come on
the top of the list of control measures which require frequent modiﬁcation and
updating due to continuous antigenic drift and sporadic antigenic shifts in the viral
surface glycoproteins reviewed by Webster and Govorkova [1].
Hemagglutinin (HA) represents the most immunogenic inﬂuenza surface
antigen, which determines host immune responses to the infections [2, 3].
Mutations which take place in the HA affect the immune response, therefore,
annual updating of the HAmolecule included in the used anti-inﬂuenza vaccines is
essential to ensure their efﬁcacy [4]. Relying on vaccines which were tailored
based on antigenically distantly related inﬂuenza strains to any of the highly
pathogenic avian inﬂuenza (HPAI) H5N1 clades may be among the reasons for the
poor immunological and protective capacity of such vaccines and this was clearly
seen in Egypt upon using the commercial vaccine Volvac which is based on the
A/Ck/Mexico/232/94 (H5N2) virus [5].
Another major inﬂuenza glycoprotein for viral classiﬁcation, infectivity,
and pathogenesis is the neuraminidase (NA) which represents the major target
for discovery of anti-inﬂuenza drug as it cleaves neuraminic (sialic) acid to
which new virions are bound and thus facilitates their exocytosis from host cells
[6–8]. Thus, emerging mutations in sequences of NA from new inﬂuenza
pandemics would change response to NA inhibitors and might result in resis-
tance to therapy [9].
In addition to immunogenic viral antigens, adjuvants play major role in the
immunological outcome to a given vaccine [10]. As examples for the used
adjuvants in commercial anti-inﬂuenza vaccines, Advax™ is a polysaccharide
based on delta inulin [11], MF59 is an oil-in-water emulsion [12] and phosphati-
dylcholine bilayer liposomes in which viral NA and HA embedded a formula
known as virosomal adjuvanted inﬂuenza vaccine which has the commercial name
Inﬂexal® V reviewed by Herzog et al. [13].
Due to its highly pathogenic nature, the immune responses to both HA and
NA of avian inﬂuenza isolates which caused outbreaks in Egypt were not studied.
Also the capacity of various adjuvants and routes of administration to modify the
immunological outcomes of vaccines based on local Egyptian strains were not
addressed.
Therefore, here we generated a reassorted virus presenting the HA5 and
NA1 of a HPAI virus on a low pathogenic PR8-H1N1 background by reverse
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genetics [14] and used its killed form to immunize mice. In addition, we
supplemented killed virus with extracts of two plants to investigate their immu-
nomodulatory value upon changing routes of immunization. The used extracts
from Echinacea purpurea (E) and Nigella sativa (N) were previously reported for
their immunomodulatory effects [15–18].
The ultimate goals of the work were to dissect the inﬂuenza-speciﬁc cellular
and humoral responses and the adjuvant-induced non-speciﬁc responses elicited in
mice treated with the killed reassorted virus supplemented by these natural extracts
and to identify the route of immunization that mediates the best immunological
outcome.
Materials and Methods
Propagation of virus
The killed reassorted virus was generated by reverse genetics (rg) of HA of a
highly pathogenic avian H5N1 inﬂuenza isolate from Egypt on PR8-H1N1
background. The virus seed used to prepare the vaccine strain rg [A/chicken/
Egypt/Q1995D/2010 (H5N1)], which was propagated in Madin–Darby canine
kidney (MDCK) cells and titrated by the plaque infectivity assay as previously
reported by Hoffmann et al. [14].
Preparation of the vaccine
The rg Q1995 virus [A/chicken/Egypt/Q1995D/2010 (H5N1)] was propa-
gated in pathogen-free embryonated chicken eggs (SPF-ECE; Nil S.P.F., Fayoum,
Egypt). The virus particles were chemically inactivated by mixing the allantoic
ﬂuid with β-propiolactone. Complete inactivation of any infectious viral particles
was further conﬁrmed by co-incubating the β-propiolactone-treated allantoic
ﬂuid with MDCK cells and excluding emergence of any cytopathic effects
microscopically for 72 h.
Adjuvant from plant origin
An amount of 3.5 mg/100 μl phosphate-buffered saline (PBS) from the
pressed juice of E-dried powder (Sekem Erosp Co., Cairo, Egypt) was prepared
according to the method of Mishima et al. [16]. An amount of 20 μl from N oil
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(Sekem Erosp Co.) was completed to 100 μl by PBS according to the published
method by Assayed [19].
Formulation of the inactivated virus vaccines with the adjuvants from plant origin
E-dried powder (3.5 mg/100 μl PBS) was mixed with the vaccine and
homogenized for 10 min at room temperature (RT). The resulting formulation
from mixing V with E was called VE. N oil was mixed with the vaccine at a
concentration of 20% (2 ml N oil+ 8 ml rH5N1 2010). The vaccine and N oil were
mixed well by homogenizer for 10 min at RT [V with N (VN)]. The used dose of
VN was 100 μl/mouse.
Immunization protocols
Sixty female Swiss albino mice weighing 15–27 g were used for the study.
The number of control (C) and immunized mice by E, N, V, VE, or VN per each
group was 5. Animals were fed on a standard diet and maintained at ambient
temperature according to the animal welfare protocols of the National Research
Centre (NRC) in Egypt. Anesthesia procedures complied with the guidelines of the
National Institutes of Health in the USA and were approved by the Medical Ethical
Committee of the NRC (registration number: 11032).
Individual mice groups received either intraperitoneal immunization (IPI) or
intramuscular immunizations (IMI) with, E, N oil, the inactivated vaccine contain-
ing no adjuvant (V), or with the abovementioned plants (VE and VN). The last
group kept as naïve (C).
Separation of sera and collection of lymphoid organs
Blood samples were collected from optical plexus of individual mice at 1st-
and 2nd-week post-priming and boosting. Sera were separated by centrifugation at
10,000g, divided into multiple aliquots, and frozen at −80 °C till being used. After
2-week post-boosting animals were sacriﬁced, lymphoid organs [mesenteric lymph
nodes (MLNs) and thymus] were dissected and used for immunophenotyping
analysis.
Detection of IgM and IgG levels in sera from immunized and control mice by ELISA
Assays were carried out as previously described by Bahgat et al. [20]. Plates
were coated with 50 μl/well inactivated appropriately diluted virus antigen and
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blocked using 100 μl/well of PBS with Tween 20 containing 5% fetal calf serum
(PBST-FCS). Diluted sera in PBST-FCS were applied 50 μl/well and plates were
incubated at 37 °C for 2 h. To detect total IgM and IgG, diluted peroxidase-
conjugated anti-mouse IgM and IgG (KPL, Gaithersburg, MD, USA) in PBST-
FCS were added (50 μl/well). To develop the reaction, the colorimetric substrate
O-phenylenediamine (Sigma, St. Louis, MO, USA) was used in presence of H2O2
and the enzymatic reaction was stopped using 2 M HCl. The changes in optical
densities were recorded at λmax 490 nm using a multi-well plate reader (Sunrise,
Tecan Austria GmbH, Grödig, Austria).
Immunophenotyping analysis of different lymphocytes populations
Immunophenotypic staining of different lymphocytes was done according to
Maghraby and Bahgat [21]. MLN and thymus were excised, gently teased in Petri
dishes containing PBST-FCS using glass slides. Pooled cells were washed three
times with PBST-FCS by centrifugation at 1,500 g and 4 °C for 10 min. CD4+,
CD8+ T- and B-lymphocytes were labeled with FITC-conjugated monoclonal
antibodies obtained from Biolegend (San Diego, CA, USA) and KPL, respectively.
To calculate the mean percentage of each cell population, green ﬂuorescence stained
cells were counted in a minimum of 100 viable pooled cells using a ﬂuorescence
microscope (Zeiss Axioskop, Jena, Germany).
Statistical analysis
Statistical analysis and plots were performed using the GraphPad PRISM
version 5 software. The results were expressed as mean ± standard deviation (SD).
Means, SDs, and degree of signiﬁcance were calculated using the unpaired data
comparison application of the Student’s t-test included in the software. Differences
were considered signiﬁcant when P values were <0.05. The number of asterisks
represents the degree of signiﬁcance where * means P < 0.05, ** means
P < 0.005, and *** means P < 0.0005, whereas “ns” means not signiﬁcant.
Results
Humoral immune responses
Kinetics and effect of route of immunization on the IgM response. At the 1st-
week post-immunization except for mice which received the VN intramuscularly,
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all other immunized mouse groups through the IM route (Figure 1A) or IP route
(Figure 1B) showed signiﬁcantly higher IgM levels than control mice. At 1st-week
post-IM immunization (WPIMI) or 1st-week post-IP immunization (WPIPI), the
highest IgM levels were recorded in the treated mice with E alone which was
signiﬁcantly higher than in the rest of mouse groups.
At the 2nd WPIMI (Figure 1C), except for mice which received the N alone,
all immunized mice showed signiﬁcantly higher IgM levels than control mice.
Although mice which received the supplemented vaccine with the N (VN) showed
the highest levels of IgM, differences were ns compared with other various
immunized mouse groups (Figure 1C). At the 2nd WPIPI, all treated animals
showed signiﬁcantly higher levels of IgM compared with control mice
(Figure 1D).
The highest IgM levels were detected in sera from treated mice with V and
levels were signiﬁcantly higher than in mouse groups which received other
treatments except for those who received E (Figure 1D). At the 3rd WPIMI or
WPIPI, mice which received various treatments showed uniformly signiﬁcantly
higher IgM levels compared with control animals (Figure 1E and 1F). In the IM
groups, peak IgM levels were seen in the mice which received the VN which were
signiﬁcantly higher than in the rest of the groups except for mice which received
the un-supplemented V (Figure 1E).
In the IP groups, the peak levels were seen in sera from immunized mice
with the un-supplemented V which were signiﬁcantly higher than in the rest of the
groups except for mice which received the supplemented vaccine with N
(Figure 1F). At the 4th WPIMI, unlike other treatments neither E nor N induced
any signiﬁcant changes in the IgM levels compared with control mice and the peak
IgM level was obtained in mice which received the supplemented vaccine with N
which were signiﬁcantly higher than all other groups (Figure 1G).
While, except for IP immunization with N, various other IP immunizations
resulted in signiﬁcant elevations in the IgM levels and the peak levels were
obtained in mice which received the un-supplemented vaccine which were
signiﬁcantly higher than all other groups (Figure 1H). Interestingly, at 2nd, 3rd
and 4th WPIMI, although N alone did not induce high IgM responses, supple-
menting the vaccine with N induced the best IgM response compared with all other
groups. Also, it was obvious that the best IgM response in case of both routes of
immunizations at the earliest time point was induced by E alone and this was later
inverted in all later time points. Of note, the outcome of the IM immunization was
always better than the IP route.
Kinetics and effect of route of immunization on the IgG response. At the 1st
WPIMI or WPIPI (Figure 2A and 2B), various treatments caused signiﬁcant
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Figure 1. Detection of IgM levels in sera from mice immunized by anti-HPAI vaccine (V)
preparation supplementing with Echinacea purpurea (E) and Nigella sativa (N) via two routes of
immunizations, i.e., intramuscular (IMI) or intraperitoneal (IPI). A: 1st week of IMI. B: 1st week
of IPI. C: 2nd week of IMI. D: 2nd week of IPI. E: 3rd week of IMI. F: 3rd week of IPI. G: 4th week of
IMI. H: 4th week of IPI. The number of control and immunized mice per each group was 5.
Differences were considered signiﬁcant when P values were <0.05. The number of asterisks
represents the degree of signiﬁcance. *P < 0.05, **P < 0.005, and ***P < 0.0005. ns: not
signiﬁcant
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Figure 2. Detection of IgG levels in sera from mice immunized by anti-HPAI vaccine
(V) preparation supplementing with Echinacea purpurea (E) and Nigella sativa (N) via two routes
of immunizations, i.e., intramuscular (IMI) or intraperitoneal (IPI). A: 1st week of IMI. B: 1st week
of IPI. C: 2nd week of IMI. D: 2nd week of IPI. E: 3rd week of IMI. F: 3rd week of IPI. G: 4th week
of IMI. H: 4th week of IPI. The number of control and immunized mice per each group was 5.
Differences were considered signiﬁcant when P values were <0.05. The number of asterisks
represents the degree of signiﬁcance. *P < 0.05, **P < 0.005, and ***P < 0.0005. ns: not
signiﬁcant
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increases in the IgG levels compared with levels in control animals and the most
signiﬁcant increases were observed in the case of immunizations with N followed
by E. In case of the IP immunization (Figure 2B), supplementing the vaccine
with N resulted in a signiﬁcant induction of IgG compared with the induced IgG
response with the V alone suggesting an immune stimulatory effect of the N.
At the 2nd-week post-immunization via the two routes (Figure 2C and 2D),
all treatments uniformly caused signiﬁcant increases in the IgG response. In case
of the IM immunization (Figure 2C), the highest IgG levels were obtained upon
treatment with V or VN, whereas the least IgG induction was obtained upon
treating mice with E or VE. Unlikely, in case of the IP immunization (Figure 2D),
the highest IgG levels were obtained upon treatment with E and VN. The distinct
differences in the trend of the IgG responses between the IP (Figure 2D) and the
IM immunizations (Figure 2C) suggest immunization route-speciﬁc immune
response.
Both at the 3rd- and 4th-week post-immunization via the two immunization
routes (Figure 2E–2H), various treatments differentially induced signiﬁcant
increases in the IgG response compared with control levels and the most
signiﬁcant increases were shown upon treatment with VN, V, and VE.
Cellular immune responses
Thymus cells (Figure 3). At the 4th WPIMI (Figure 3A), the CD4+ thymo-
cytes showed signiﬁcant increases only upon treatment with the E, the V, and the
VE with the highest mean percentage recorded in case of VE. Whereas IP
immunization clearly induced better induction of CD4+ thymocytes compared
with the IM route as various IP treatments (Figure 3B) caused highly signiﬁcant
increase in the mean percentage of such cell population compared with control
levels. As for CD8+ cells, the most signiﬁcant IM induction (Figure 3C) was
obtained by the V and the VN, whereas the best IP stimulation was induced by the
N, the VE, and the VN (Figure 3D).
Mesenteric lymph node cells. At the 4th WPIMI, various treatments caused
signiﬁcant increases (Figure 4A and 4C) in the mean percentage CD4+ and CD8+
cells compared with the control level. As for the IP immunizations, V and VE
caused signiﬁcant increases in the CD4+ cells (Figure 4B), whereas V, VE, and
VN, caused signiﬁcant increases in the CD8+ cells (Figure 4D). Notably, IM with
N alone caused signiﬁcant decrease in the mean percentage CD4+ counts
compared with the control levels (Figure 4A). At the 4th-week post-immunization
via the two routes, various treatments caused signiﬁcant increases in the mean
percentages of the B cells compared with the control levels and the most
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signiﬁcant IM B-cell induction was obtained by the N alone, whereas most
signiﬁcant IP induction was obtained by the VN (Figure 4E and 4F).
Discussion
Successful outcome of vaccination can be inﬂuenced by vaccine formula-
tion, type of adjuvant, and immunization route. While an immunization route for a
given vaccine may induce protection against an infection, the same route may not
lead to the desired protection against other infection [22, 23]. In fact, not only
vaccine seeds but also adjuvants used in combination with vaccines are essential in
achieving optimal protective immunity [24, 25].
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Figure 3.Mean percentage of CD4+ and CD8+ thymocytes at 4th week of immunization from mice
immunized by anti-HPAI vaccine (V) preparation supplementing with Echinacea purpurea (E) and
Nigella sativa (N) via two routes of immunizations, i.e., intramuscular (IMI) or intraperitoneal (IPI).
A: Mean percentage of CD4+ thymocytes via IMI. B: Mean percentage of CD4+ thymocytes via
IPI. C: Mean percentage of CD8+ thymocytes via IMI. D: Mean percentage of CD8+ thymocytes
via IPI. The number of control and immunized mice per each group was 5. Differences were
considered signiﬁcant when P values were <0.05. The number of asterisks represents the degree of
signiﬁcance. *P < 0.05, **P < 0.005, and ***P < 0.0005. ns: not signiﬁcant
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Figure 4.Mean percentage of CD4+, CD8+, and B-MLN lymphocytes at 4th week of immunization
from mice immunized by anti-HPAI vaccine (V) preparation supplementing with Echinacea
purpurea (E) and Nigella sativa (N) via two routes of immunizations, i.e., intramuscular (IMI) or
intraperitoneal (IPI). A: Mean percentage of CD4+ lymphocytes via IMI. B: Mean percentage of
CD4+ lymphocytes via IPI. C: Mean percentage of CD8+ lymphocytes via IMI. D: Mean percentage
of CD8+ lymphocytes via IPI. E: Mean percentage of B-lymphocytes via IMI. F: Mean percentage
of B-lymphocytes via IPI. The number of control and immunized mice per each group was 5.
Differences were considered signiﬁcant when P values were <0.05. The number of asterisks
represents the degree of signiﬁcance. *P < 0.05, **P < 0.005, and ***P < 0.0005. ns: not signiﬁcant
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Although poultry but not mouse represents the natural ﬁnal host for avian
inﬂuenza infection, several recent studied evaluated immunogenicity and protec-
tive capacity of anti-H5N1 avian inﬂuenza vaccines in mice [26–28]. In fact, most
of the available vaccine strains against avian inﬂuenza including the one we used
in the present work are generated by reverse genetics [14] on the background of the
mouse adapted PR8-H1N1 strain [29] which makes mouse a relevant model for
characterizing immune responses induced by such vaccines. Other convincing
reasons for us to use mouse as an animal model in our experiments are feasibility
of its maintenance, handling, and availability of immunological reagents for post-
vaccination studies of both humoral and cellular responses [30].
Induced humoral and cellular immune responses due to un-supplemented killed
reassorted virus (V)
The induced IgM peaks both at 2nd, 3rd, and 4th WPIPI and IgG peaks both at
2nd and 3rd WPIMI by V reﬂect route-speciﬁc immune stimulation which agrees
with Gao et al. [31] who demonstrated that IMI with whole inactivated human
adenovirus particles was more protective than intranasal immunization. On
contrary, although using a different vaccine and different routes of immunization,
Ledgerwood et al. [32] found that changing route of immunization with a DNA
vaccine encoding the HA molecule H5 from IMI to intradermal did not lead to a
signiﬁcant advantage in the immunological outcome.
In the same direction, our cellular results upon immunization with V showed
the capacity of both IMI and IPI to induce proliferation of CD4+ but IMI only led
to stimulate CD8+ thymocytes, while both routes induced signiﬁcant increases in
CD4+T, CD8+T, and B-MLN cells. Along the same lines and although using
different strains and having different aims, in a study where aiming at inducing
cross-protection against heterologous human inﬂuenza subtypes, Wang et al. [33]
showed capacity of IMI but not IPI with live PR8-H1N1 to protect against a
challenge infection with H3N2 although both routes equally stimulated CD8+
T cells which allows us to suggest that in their case-protective immunity is
CD8+-independent. The authors attributed the privilege of the IMI above IPI to
the proximity of the IMI to induce local immune responses in the draining lymph
node unlike the uneasy stimulation of the distal lymphoid organs in case of IPI
which is always accompanied by systemic dilution of the antigens.
E. purpurea and N. sativa (E and N)
The phenomenon of the route-speciﬁc immune stimulation was also obvi-
ous. However, in case of both extracts, the IPI elicited better humoral immune
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responses than the IMI. Extracts of E and N were able to increase the titer of IgM
and IgG in case of both routes (IMI and IPI) at the earliest time point of
administration. We also showed that this response was inverted at 3rd and 4th
WPIMI and WPIPI of injections. Controversial results were reported on the
immunological effects of action of E where Rehman et al. [34] described the
capacity of its extract to induce IgG production in rats and Mishima et al.
[16] recorded the opposite. The inverted effect of the Echinacea extract on IgG
production seen in our results was explained by Hayashi et al. [35] on the capacity
of the same extract to suppress the humoral immune responses through stimulating
IFN-γ production.
The signiﬁcant stimulation of MLN CD4+, CD8+, B cells, and CD8+
thymocytes due to IPI of E and CD4+ thymocytes due to IMI of E were in
agreement with Redondo [17] who attributed the ability of E to stimulate the
immune system by enhancing both production of antibodies and T-cell
responses, Bodinet and Freudenstein [15] who demonstrated the capacity of
extracts from different parts of Echinacea sp. to activate neutrophils, macro-
phages, T cells, and B cells. The signiﬁcant increases in MLN-B cells and CD8+
thymocytes induced by IPI with N were consistent with Salem and Hossain [18]
who reported that N enhanced the cellular immunity and with Islam et al. [36]
who found that some constituents of N exert a stimulatory effect toward
T-cell-mediated immune responses. The antiviral effect of the N oil was reported
by Salem and Hossain [18], Abuharfeil et al. [37] to be associated with
enhancing CD4+ and CD8+ cell responses, and macrophages, and augmenting
their ability to produce IFN-γ.
Supplemented killed virus with E or N (VE and VN)
The signiﬁcant decreases seen in the levels of IgM at 3rd and 4th WPIMI or
WPIPI with the supplemented vaccine by E compared with the V alone reﬂected a
regulatory effect of the E on the induced IgM response by the V. This could be
partially explained to be due to denaturing some of the antigenic determinant of the
V by the E [38–41]. It falls in agreement with a previous report on a possible
immune suppressive effect by E [35].
The observed signiﬁcant increase in the IgM upon IMI of mice with
supplemented V with N in comparison with the treated animals with the un-
supplemented V reveals an immunostimulatory effect of the N. This can be due to
a direct effect of the plant extract on the host immune response [18] or due to an
indirect effect of the N that leads to chemical structural modiﬁcation (epitope
exposure) of the V [38–41]. Although IPI with VN still caused a signiﬁcant
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increase in IgM levels compared with the control animals, interestingly, an
opposite effect was seen, i.e., signiﬁcantly less stimulation of IgM in case of
treating mice with supplemented vaccine by N compared with V alone.
Since the levels of IgM both in case of the IMI and IPI with V alone were
comparable, the drop in the IgM level upon supplementing the V by N in case of
the IPI cannot be only interpreted to be due to changing the site of immunization
but it rather opens a question of an additional unknown factor which modulates the
exerted effect by N in either of the two site. This unknown factor makes the effect
of N stimulatory in the case of IMI and regulatory in the case of IPI. The signiﬁcant
enhancement of the IgG response both at 4th WPIMI, 2nd and 3rd WPIPI upon
supplementing the V with N compared with the un-supplemented B further
conﬁrms the immunostimulatory effect of N at the humoral level.
The obvious increase in the counts of the CD4+ thymocytes in animals
which received IMI by the supplemented vaccine with E compared with mice
which received the un-supplemented V or the E separately via the same route
further suggests the improvement of the antigenicity of the V by the E which can
be attributed to induced structural changes. This agrees with previous reports on
conformational changes induced in some vaccines due to treatment with adjuvants
[38–41]. As for the CD8+ thymocytes, absence of signiﬁcant differences between
animals which received IMI with either V, VE, or VN and the obvious signiﬁcant
differences between their levels in the three animal groups compared with mice
which received either E or N alone conﬁrm that the induction is mainly due to the
V antigens.
The signiﬁcant drop in the level of CD4+ thymocytes seen in mice who
received IPI with VE compared with mice immunized with E alone via the same
route reﬂects the hindering effect of the V on the stimulatory effect of the E and
the opposite was seen for CD8+ thymocytes which reﬂected that E enhanced the
antigenicity of V [15]. The almost identical levels of CD4+ and CD8+
thymocytes in mice who received IPI with either N or VN and the signiﬁcantly
higher levels of such cells in both mice groups compared with animals who
received the un-supplemented V suggest that the stimulatory effect is mainly due
to N alone [18].
The absence of any signiﬁcant differences between levels of MLN-CD4+
cells in mice treated via the IM route with either E or V or VE suggests that
supplementing the vaccine with the E did not improve the immune outcome
stimulated by either of them. Unlikely the immune stimulation of MLN-CD4+
cells in IM- or IP-treated mice with or VN was due to the V but not the N since
levels of such cells were almost identical in mice treated with either V and VN,
nevertheless, levels in both groups were signiﬁcantly higher than in mice treated
with N alone and the same holds true for IP-treated mice with VE and V.
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Our results showed that the stimulation of the MLN-CD8+ cells in case of
the IMI was due to either E or N upon being combined with V and the opposite
was seen for the same cell subset in case of IPI conﬁrming route-speciﬁc response.
Also, our IMI data clearly showed the enhancement of the MLN-B cells due to
combining the E and V as it gave better response than either E or V separately
which might be due to modiﬁcation of the antigenicity of the V by the E; however,
the resulting stimulation of such cells with the VN was mainly due to N as both
mouse groups showed comparable levels of the cells which was in either case
signiﬁcantly higher than that induced by the V. Last but not least, the enhanced
MLN-B cells in case of IPI mice with the VN was due to combined effect of both
components as it showed better stimulation than either N or V; however, the
obtained effect in case of VE was clearly due to the V.
Conclusions
Altogether, the study highlights the value of the present work to identify
economic natural adjuvants which can induce non-speciﬁc immunity against
circulating avian inﬂuenza viruses and increase efﬁcacy of the used vaccines
through either of the two used routes of immunization.
IM immunization with the supplemented reassorted killed virus by the
N stimulated the humoral immune responses in comparison with the extract-free
vaccine which highly suggests the immune stimulatory adjuvant effect of this plant
extract.
The distinct differences in the trend of both the cellular and humoral
responses resulting from the IPI and IMI by the supplemented, un-supplemented
vaccine as well as the plant extracts alone clearly suggest route-speciﬁc immune
modulation which was always privileged in case of IMI.
Last but not least, the capacity of the E to downregulate both the induced
cellular and humoral responses by the V highlights the possible potential useful-
ness of such plant extract in supplementing vaccines prior to immunizing
hyperimmune or autoimmune patients who are known to undergo severe inﬂam-
matory responses upon being vaccinated which sometimes can be fatal which goes
beyond the original aim of this study.
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